CD8A and colorectal carcinoma: Moreover, a phase II randomized study (CAPability-01) in patients with chemo-refractory microsatellite-stable CRC showed that adding the HDACi Tucidinostat to PD-1 blockade and anti-VEGF therapy significantly increased intratumoral CD8+ T cell density and objective response rates compared to PD-1 inhibition alone [121].